Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer.
Dana Farengo Clark, Scott T Michalski, Rashmi Tondon...
https://pubmed.ncbi.nlm.nih.gov/32051609/Actively Recruiting
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-02-05
100
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying the cancer risks linked to specific changes called loss-of-function variants in the CTNNA1 gene. These gene changes may increase the chance of hereditary cancers such as gastric and breast cancer. The study aims to better understand how these genetic changes relate to cancer development and if certain gene types are connected to specific cancer patterns. This knowledge will help improve risk management for individuals carrying these gene variants. Participants will provide personal and family medical history through an online system. The study focuses on people who carry CTNNA1 loss-of-function variants or their first-degree relatives. There is no treatment involved instead, data collection is observational to assess how these gene changes relate to cancer occurrence. During the study, researchers will gather detailed personal and family history information from participants. They will monitor the rate of cancer among gene variant carriers and explore the relationship between CTNNA1 genotypes and cancer types. The study is expected to last about one year, with all participation done through data entry without any medical procedures. Safety and compliance are monitored through questionnaire and data review.
CONDITIONS
CTNNA1 Familial Expansion Study
B
Bryson W Katona, MD, PhD
D
Dana Farengo Clark, MS, LCGC
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Abramson Cancer Center at Penn Medicine
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - Up to 1 year
Participants provide personal medical and family history information related to CTNNA1 gene variants through an online data entry system and are observed for cancer outcomes.
Ongoing data entry and updates as needed
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Dana Farengo Clark, Scott T Michalski, Rashmi Tondon...
https://pubmed.ncbi.nlm.nih.gov/32051609/Abramson Cancer Center at Penn Medicine
Lead Sponsor